That's a really good post, TheFreeDoc, and pretty much sums up the situation as I see it as well. The key wording I think you nailed is, "The answer to that, on the surface, has been largely non reactive". To investors who aren't intimately familiar with the industry or those who only check in periodically nothing has really changed other than a few supplier partnerships and some R&D work with a few others.
The reality of this is the change in strategy a few years back is now starting to show results with key partnerships through major distributors and small/medium players (ie. Scienion, Qiagen, etc.) who partner with the big boys. Distributing through Sigma and others gets the product into the hands of the scientists which, in theory, ultimately leads to bespoke solutions and long-term supply/partnership arrangements for inclusion on manufacture of products. On the surface it seems not much has changed, but dig a little and you learn of the huge strides the business has taken in the last 12 months towards profitability in the near future.
Couple that progress with a pending accretive acquisition (allegedly) which fast-tracks the business not only into profitability, but manufacture capability, presence in Europe, accredited facility and things are maybe not quite as they appear on the surface. For those in the know, this looks to be a very strong opportunity. For those not, I'll try and pick up a few of theirs should they not take up any/all of their allotment.
ALL IMHO, DYOR, FWIW, MSDB, blah blah blah.....
Expand
